Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI-001 in in vitro Models of Prostate Cancer Drug Resistance.

"Conflict of interest The authors declare no conflict of interest."

"This study was funded by the Prostate Cancer Foundation through a Young Investigator Award to M.A. The work performed by R.C.B., F.J.P.A, J.I and D.R.S. was funded by UKRI grants, as well as by EPSRC (EP/P020291/1). For the purpose of Open Access, the author has applied a CC‐BY public copyright licence to any Author Accepted Manuscript (AAM) version arising. R.C.B. acknowledges Trinity College Cambridge. Z.M. acknowledges funding from a doctoral college, University of Surrey PhD studentship award. F.J.P.A. acknowledges Fundación Ramón Areces (reference BEVP31A6160) and Marie Skłodowska‐Curie Individual Fellowships (MSCA‐IF‐2020, grant number 101025271). We are grateful to Prof. Aria Baniahmad (University of Jena) and Prof. Scott Dehm (University of Minnesota) for providing expression vectors used in this study."